Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio company Thrombotech Ltd. has begun a Phase I clinical trial of its peptide-based stroke treatment. The safety trial will include 40 healthy persons, and is due to be completed by the end of the year.
Clal Biotech owns 41% of Thrombotech, Hadasit Bio Holdings Ltd. (TASE:HDST) owns 35%, and Ofer Hi Tech Ltd. owns 25%.
Earlier this week, Clal Biotech announced that it will bring in new investors to burn treatment subsidiary MediWound Ltd., a transaction which will reduce its stake in the company to under 50%. Clal Biotech added that it expects a capital gain of NIS 210-330 million on the deal
Clal Biotech's share rose 1% by midday today to NIS 24.40.
Published by Globes [online], Israel business news - www.globes-online.com - on April 15, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010